Basit öğe kaydını göster

dc.contributor.authorAricigil, Mitat
dc.contributor.authorMuluk, Nuray Bayar
dc.contributor.authorSakarya, Engin Umut
dc.contributor.authorSakalar, Emine Guven
dc.contributor.authorSenturk, Mehmet
dc.contributor.authorReisacher, William R.
dc.contributor.authorCingi, Cemal
dc.date.accessioned2020-06-25T18:16:04Z
dc.date.available2020-06-25T18:16:04Z
dc.date.issued2016
dc.identifier.citationclosedAccessen_US
dc.identifier.issn1945-8924
dc.identifier.issn1945-8932
dc.identifier.urihttps://doi.org/10.2500/ajra.2016.30.4379
dc.identifier.urihttps://hdl.handle.net/20.500.12587/6407
dc.descriptionWOS: 000390857000001en_US
dc.descriptionPubMed: 28124639en_US
dc.description.abstractObjectives: Allergen immunotherapy is the only cure for immunoglobulin E mediated type I respiratory allergies. Subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) are the most common treatments. In this article, we reviewed new routes of allergen immunotherapy. Methods: Data on alternative routes to allow intralymphatic immunotherapy (ILIT), epicutaneous immunotherapy (EPIT), local nasal immunotherapy (LNIT), oral immunotherapy (OIT), and oral mucosal immunotherapy (OMIT) were gathered from the literature and were discussed. Results: ILIT features direct injection of allergens into lymph nodes. ILIT may be clinically effective after only a few injections and induces allergen-specific immunoglobulin G, similarly to SCIT. A limitation of ILIT is that intralymphatic injections are required. EPIT features allergen administration by using patches mounted on the skin. EPIT seeks to target epidermal antigen-presenting Langerhans cells rather than mast cells or the vasculature; this should reduce both local and systemic adverse effects. LNIT involves the spraying of allergen extracts into the nasal cavity. Natural or chemically modified allergens (the latter, termed allergoids, lack immunoglobulin E reactivity) are prepared in a soluble form. OIT involves the regular administration of small amounts of a food allergen by mouth and commences with low oral doses, which are then increased as tolerance develops. OMIT seeks to deliver allergenic proteins to an expanded population of Langerhans cells in the mucosa of the oral cavity. Conclusions: ILIT, EPIT, LNIT, OIT, and OMIT are new routes for allergen immunotherapy. They are safe and effective.en_US
dc.description.sponsorshipContinuous Education and Scientific Research Associationen_US
dc.description.sponsorshipWith the exception of data collection, the preparation of this manuscript (including design and planning) was supported by the Continuous Education and Scientific Research Associationen_US
dc.language.isoengen_US
dc.publisherSage Publications Incen_US
dc.relation.isversionof10.2500/ajra.2016.30.4379en_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleNew routes of allergen immunotherapyen_US
dc.typearticleen_US
dc.contributor.departmentKırıkkale Üniversitesien_US
dc.identifier.volume30en_US
dc.identifier.issue6en_US
dc.identifier.startpageE193en_US
dc.identifier.endpageE197en_US
dc.relation.journalAmerican Journal Of Rhinology & Allergyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster